BOOSTING AMERICAN-PRODUCED PHARMACEUTICALS: Today, President Donald J. Trump enacted an Executive Order aimed at revitalizing the domestic production of prescription drugs, including the essential ingredients and materials required for their manufacture.
- This Executive Order instructs the U.S. Food and Drug Administration (FDA) to expedite the approval process for domestic pharmaceutical manufacturing facilities by eliminating redundant and unnecessary regulatory hurdles, simplifying reviews, and collaborating with local manufacturers to provide proactive support before these facilities become operational.
- The Order also mandates the FDA to increase fees and inspections for foreign manufacturing plants.
- Further, President Trump is directing the FDA to enhance the enforcement of reporting requirements regarding the sources of active pharmaceutical ingredients from foreign producers, and to contemplate publicly listing non-compliant facilities.
- The Order tasks the Environmental Protection Agency (EPA) with hastening the establishment of facilities for the production of prescription drugs, active pharmaceutical ingredients, and other critical raw materials.
- Moreover, the Order ensures that federal agencies responsible for permitting domestic pharmaceutical manufacturing designate a single point of contact to coordinate permit applications, backed by interagency support from the White House Office of Management and Budget (OMB) to streamline the process.
SPURRING ECONOMIC GROWTH AND ENHANCING NATIONAL SECURITY THROUGH PERMITTING REFORM: President Trump is dismantling bureaucratic barriers to crucial domestic pharmaceutical manufacturing, aiming to usher in a new era of prosperity by guaranteeing access to essential medications for Americans.
- Significant challenges persist in creating a resilient, affordable domestic pharmaceutical supply chain for American patients.
- New construction projects must navigate an intricate web of Federal, State, and local regulations, from building codes to zoning laws and environmental standards, which collectively deter investment in large-scale manufacturing initiatives.
- Estimates indicate that the establishment of new manufacturing capacity for pharmaceuticals and essential inputs could take anywhere from five to ten years—an unacceptable delay from a national-security perspective.
- This Executive Order aims to shorten the timelines for setting up domestic pharmaceutical manufacturing sites by minimizing regulatory obstacles to construction.
FULFILLING PROMISES TO PRIORITIZE AMERICAN INTERESTS: President Trump is making good on his commitment to prioritize American manufacturing by ensuring the FDA favors domestic facilities over foreign counterparts.
- President Trump stated: “We don’t want to be buying our pharmaceuticals from other countries because if we’re in a war, we’re in a problem; we want to be able to make our own.”
- He further emphasized, “As we invest in the future, we will permanently bring our medical supply chains back home. We will produce our medical supplies, pharmaceuticals, and treatments right here in the United States.”
- This Executive Order builds upon actions taken during President Trump’s first term to reshore the production of essential medicines and reduce reliance on foreign suppliers.
